609.7

+1.84%↑

ALV

302.5

+0.27%↑

SAF

214.4

+2.49%↑

BBVA

9.088

-2.36%↓

65.16

-0.24%↓

609.7

+1.84%↑

ALV

302.5

+0.27%↑

SAF

214.4

+2.49%↑

BBVA

9.088

-2.36%↓

65.16

-0.24%↓

609.7

+1.84%↑

ALV

302.5

+0.27%↑

SAF

214.4

+2.49%↑

BBVA

9.088

-2.36%↓

65.16

-0.24%↓

609.7

+1.84%↑

ALV

302.5

+0.27%↑

SAF

214.4

+2.49%↑

BBVA

9.088

-2.36%↓

65.16

-0.24%↓

609.7

+1.84%↑

ALV

302.5

+0.27%↑

SAF

214.4

+2.49%↑

BBVA

9.088

-2.36%↓

65.16

-0.24%↓

Inicio・Lista de Acciones・Bayer AG

Bayer AG

Abierto

Sector Finanzas

26.44 -0.92

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

26.25

Máximo

26.695

Métricas clave
By Trading Economics
Ingresos	-2B -34M
Ventas	-2.6B 11B
P/B Media del Sector	30.9 17.821
BPA	0.94
Margen de beneficio	-0.305
EBITDA	-2.6B 1.7B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+13.97 upside

Dividendos
By Dow Jones
Próximas Ganancias	12 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-3.7B 26B
Apertura anterior	27.36
Cierre anterior	26.44

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

118 / 461 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

26.13 / 26.685 Soporte y Resistencia

Bayer AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 oct 2024, 17:03 UTC

Principales Movimientos del Mercado

Bayer Shares Plunge After U.S. Legal Setback -- Update

9 oct 2024, 14:21 UTC

Principales Movimientos del Mercado

Bayer Shares Plunge After U.S. Legal Setback

16 ago 2024, 08:28 UTC

Principales Movimientos del Mercado

Bayer Shares Surge After Appeal Win in Roundup Cancer Suit

15 ago 2024, 21:43 UTC

Ganancias

Bayer's Monsanto Wins Appeal in Roundup Cancer Suit

6 ago 2024, 10:56 UTC

Ganancias

Bayer Posts Net Loss as Tough Agriculture Market Bites -- Update

6 ago 2024, 09:00 UTC

Ganancias

Correction to Bayer Article

6 ago 2024, 06:29 UTC

Ganancias

Bayer Posts Net Loss, Dragged by Weaker Crop-Science Performance

14 may 2024, 13:21 UTC

Ganancias

Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update

23 ago 2024, 08:51 UTC

Charlas de Mercado

BMW's EV Coup Over Tesla in Europe Shows Strength as Tesla Products Age -- Market Talk

16 ago 2024, 14:21 UTC

Charlas de Mercado

Bayer's Appeal Win Could Be First Step to End Roundup Litigation -- Market Talk

16 ago 2024, 08:58 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Applied Materials, H&R Block, Bayer, Bavarian Nordic -- WSJ

6 ago 2024, 10:47 UTC

Charlas de Mercado

Bayer Could Face Consensus Earnings Downgrades Amid Currency Headwinds -- Market Talk

6 ago 2024, 08:55 UTC

Charlas de Mercado

Ganancias

Bayer's 2Q Beat Boosted By Pharma Business -- Market Talk

6 ago 2024, 08:20 UTC

Charlas de Mercado

Ganancias

Bayer's 2Q Results Are a Mixed Bag -- Market Talk

6 ago 2024, 06:57 UTC

Charlas de Mercado

Ganancias

Bayer 2Q Results Could Lead to Muted Share Price Response -- Market Talk

6 ago 2024, 05:34 UTC

Ganancias

Bayer Saw 2024 Core EPS Between EUR5.10 and EUR5.50

6 ago 2024, 05:34 UTC

Ganancias

Bayer Saw 2024 Ebitda Before Special Between EUR10.7B and EUR11.3B

6 ago 2024, 05:33 UTC

Ganancias

Bayer Backs 2024 View

6 ago 2024, 05:33 UTC

Ganancias

Analysts Saw Bayer 2Q Ebitda Before Special Items at EUR2.08B

6 ago 2024, 05:33 UTC

Ganancias

Bayer 2Q Ebitda Before Special Items EUR2.11B

6 ago 2024, 05:32 UTC

Ganancias

Analysts Saw Bayer 2Q Net Pft at EUR70M

6 ago 2024, 05:32 UTC

Ganancias

Bayer 2Q Net Loss EUR34M

6 ago 2024, 05:31 UTC

Ganancias

Analysts Saw Bayer 2Q Core EPS at EUR0.84

6 ago 2024, 05:31 UTC

Ganancias

Bayer 2Q Core EPS EUR0.94

6 ago 2024, 05:31 UTC

Ganancias

Bayer 2Q EBIT EUR525M

6 ago 2024, 05:30 UTC

Ganancias

Analysts Saw Bayer 2Q Rev at EUR10.82B

6 ago 2024, 05:30 UTC

Ganancias

Bayer 2Q Rev EUR11.14B

12 jul 2024, 07:05 UTC

Charlas de Mercado

Bayer's Cost-Savings and Cash Delivery Key Focus for 2Q -- Market Talk

5 jun 2024, 09:57 UTC

Acciones populares

Stocks to Watch Wednesday: CrowdStrike, HPE, Dollar Tree -- WSJ

14 may 2024, 11:00 UTC

Charlas de Mercado

Ganancias

Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk

Comparación entre iguales

Cambio de precio

Bayer AG Esperado

Precio Objetivo

By TipRanks

13.97% repunte

Estimación a 12 meses

Media 30.11 EUR 13.97%

Máximo 34 EUR

Mínimo 26 EUR

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bayer AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Bayer AG Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

26.13 / 26.685Soporte y Resistencia

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

118 / 461 Clasificación en Finanzas

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non